Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal MNJ (Malang Neurology Journal)
Ardianto, Christian
Unknown Affiliation
Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
EFFECT OF INTRAVENOUS ADMINISTRATION OF SECRETOME ON MALONDIALDEHYDE LEVELS IN ROTENONE-INDUCED PARKINSON'S DISEASE RATS Aliza, Sharla; Sidharta, Veronika Maria; Sasmita, Poppy Kristina; Ardianto, Christian; Barus, Jimmy
MNJ (Malang Neurology Journal) Vol. 11 No. 1 (2025): January
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.01.03

Abstract

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder with an increasing prevalence. Oxidative stress is known to contribute to the development of PD through lipid peroxidation, which causes damage to the substantia nigra pars compacta. Lipid peroxidation produces malondialdehyde (MDA), which is known to be elevated in PD patients. Up till now, there is no cure for PD, and the available therapies are only symptomatic. The secretome from Mesenchymal Stem Cell (MSC) has antioxidant and neuroprotective components, making it a potential therapeutic agent that may slow the progression of PD. Objective: This study seeks to determine the effect of MSC secretome on oxidative stress in rotenone-induced PD rats. Methods: This research was an in-vivo experiment conducted with 30 male Sprague Dawley rats, divided into sham control, rotenone (+) secretome (-), and rotenone (+) secretome (+) groups. Rotenone (2.75 mg/kgBW) was administered for seven days to induce a PD model. Secretome administration (1 mg/ml) was carried out on days 3, 5, and 7. MDA levels were determined using the sandwich ELISA method. Results: This study found no significant difference in MDA levels among the three groups (p = 0.203). The sham control group had the lowest MDA 1.32(0.53) nmol/mL, followed by the rotenone (+) secretome (+) group 1.56(0.33) nmol/ml, and the highest MDA was observed in the rotenone (+) secretome (-) group 1.88(0.14) nmol/mL. Conclusion: Administration of MSC secretome did not significantly cause changes in plasma MDA levels of rotenone-induced Parkinson Disease rats.
EFFECTS OF MSC-DERIVED SECRETOME TOWARDS PLASMA-TOTAL CHOLESTEROL LEVELS ON ROTENONE-INDUCED PARKINSON’S DISEASE RAT MODELS Putria, Fani Mustika; Sasmita, Poppy Kristina; Sidharta, Veronika Maria; Ardianto, Christian; Barus, Jimmy
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.01

Abstract

Background: Parkinson's disease (PD), a chronic progressive neurodegenerative disease, threatens much of the world's increasingly aging population and has no promise for disease-modifying drugs, only symptomatic treatment. One potential biomarker correlates PD to the disruption of cholesterol metabolizing processes that results in formation of cytotoxic bile acids (BA) which induces mitochondrial dysfunction that leads to the decrease of dopaminergic neurons in various PD models. Objective: This study aims to determine the effect of rotenone-induction as well as MSC-Secretome administration on plasma-total cholesterol levels in rat models.. Methods: This was an experimental research using 30 male Sprague Dawley rats divided into sham control, rotenone (+) secretome (-) and rotenone (+) secretome (+). Blood was withdrawn on day 0 and day 8 and analyzed under colorimetry and spectrophotometry for its plasma-total cholesterol concentration. Results: The Tukey Post-Hoc Test showed that there was no significant difference between the sham control and rotenone (+) secretome (-)  (p = 0.073), plasma-total cholesterol level is lower in rotenone (+) secretome (-) than in the sham control. Furthermore, we were unable to prove for a significant difference between the rotenone (+) secretome (-) and rotenone (+) secretome (+) group (p= 0.234), even though in average the plasma-total cholesterol level is lower in the rotenone (+) secretome (+)  group. Conclusion: Induction of rotenone followed by an intervention of MSC-Secretome has no effect on the change in plasma-total cholesterol levels on rat models.
Co-Authors Aliza, Sharla Jimmy Barus, Jimmy Poppy Kristina Sasmita Putria, Fani Mustika Veronika Maria Sidharta